Learn about
Problem
Century-old heparin market faces ongoing shortages and significant challenges that could impact global health.
Solution
ExCulture’s novel, animal-free alternative is uniquely positioned to address the challenges faced by the current heparin market.
Supported by
What drives us?
To become the global pioneers of mixed culture fermentation for the efficient and reliable production of complex novel biopharmaceuticals.
ExCulture secures funding from the Dutch Industrial Biotech Seed Fund (managed by Capricorn Partners) and TTT Medtech
Leiden, 12th July 2024 - ExCulture B.V., a biotechnology startup focused on the development of an animal-free heparin substitute via fermentation,...
DSM Firmenich Kickstart Fund
On Friday 12th April 2024 ExCulture was announced as winner of the 2024 DSM-Firmenich Kickstart Prize, securing €50,000 after pitching to and...
Bio Spring Conference
Looking back on a successful first experience of the BioEurope Spring Conference held in Barcelona for ExCulture.We had the opportunity to make many...